Stephens downgraded Blueprint Medicines (BPMC) to Equal Weight from Overweight with a price target of $135, down from $150, after Sanofi (SNY) announced a definitive agreement to acquire Blueprint for $129 per share in cash. In conjunction with the downgrade, the analyst is dropping Blueprint as a “Best Idea Pick” and moving to cash.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint downgraded to Market Perform from Outperform at Citizens JMP
- Blueprint Medicines downgraded to Hold from Buy at TD Cowen
- Blueprint downgraded to Peer Perform from Outperform at Wolfe Research
- Blueprint Medicines downgraded to Neutral from Overweight at JPMorgan
- Blueprint Medicines downgraded to Perform from Outperform at Oppenheimer
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue